The U.S. Food and Drug Administration questions manufacturing controls at a Teva Pharmaceutical Industries plant in China, according to a Reuters article citing a regulatory filing on Thursday.
Teva received the FDA warning letter on April 10, with violations resulting from a regulatory inspection of its plant in September.
Read the full story